Results 61 to 70 of about 5,352 (210)

Altered Pharmacokinetics and Delayed Sputum Conversion in Tuberculosis Patients Co‐Infected With HIV

Tropical Medicine &International Health, Volume 31, Issue 9, Page 1261-1272, September 2026.
ABSTRACT Background HIV co‐infection affects host responses and pharmacokinetics (PK) of tuberculosis (TB) treatment. This study assessed the PK of first‐line anti‐TB drugs and clinical outcomes in patients with and without HIV co‐infection. Methods In this prospective observational study, 61 adults with sputum‐positive pulmonary TB, either confirmed ...
Aung Pyae Phyo, Richard M. Hoglund, Makoto Saito, Sein Sein Thi, Lei Lei Swe, Palang Chotsiri, Htet Ko Ko Aung, Win Pa Pa Tun, Banyar Maung Maung, Chanapat Pateekham, Wanitda Watthanaworawit, Gornpan Gornsawun, Nicholas J. White, Francois Nosten, Joel Tarning   +14 more
wiley   +1 more source

Mapping opioid exposure through prescription data and postmortem analysis of opioid drugs in multiple tissues

British Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2624-2635, August 2026.
Background and Purpose Although opioids are central to end of life (EoL) care, tissue‐level opioid exposure remains poorly understood. The objective of this study was to characterize the relationship between prescription‐derived morphine equivalent daily dose (MEDD) and measured morphine concentrations across multiple organs.
Niamh Higgins, Alan Wells, Nimish Patel, Nicole Muttera, Mattia Trunfio, Alessandra Manca, Amedeo De Nicolò, Micol Ferrara, Stefano Bonora, Jessica Cusato, Alice Palermiti, Antonio D'Avolio, Marissa Borochoff, Patricia K. Riggs, Elizabeth Hastie, Rabia S. Atayee, Stephanie Solso, Cheryl Dullano, Vanessa Gomez‐Moreno, Tara Tenenbaum, Robert Deiss, Davey M. Smith, Antoine Chaillon, Sara Gianella   +23 more
wiley   +1 more source

Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals.

, 2016
Co-formulated elvitegravir, cobicistat, tenofovir disoproxil fumarate and emtricitabine is among the preferred regimens for first-line ART. A population approach was used to characterize the pharmacokinetics of elvitegravir and cobicistat and identify ...
Csajka, C., Rotger, M., Decosterd, L.A., Aouri, M., Buclin, T., Barceló, C., Guidi, M., Gaspar, F., Panchaud, A., Cavassini, M.   +9 more
core   +1 more source

Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 531-541, August 2026.
CYP2C19 and CYP3A4 contribute to clopidogrel bioactivation. CYP2C19 no‐function alleles diminish clopidogrel's antiplatelet effects and clinical effectiveness. Coadministration of either a CYP2C19 or a CYP3A4 inhibitor may also reduce clopidogrel's antiplatelet effects and lead to phenoconversion in patients without a CYP2C19 no‐function allele (normal/
Danwei Shao, Jean G. Malavé, Joseph S. Rossi, Francesco Franchi, Ellen C. Keeley, Dominick J. Angiolillo, George A. Stouffer, Larisa H. Cavallari, Craig R. Lee   +8 more
wiley   +1 more source

Pharmacokinetic interactions between cobicistat-boosted elvitegravir and darunavir in HIV-infected patients

, 2017
[Objectives] To evaluate if there are significant drug–drug interactions between cobicistat-boosted elvitegravir and 800 mg darunavir once daily taken simultaneously, as has been suggested previously.[Methods] The study population consisted of three ...
Lopez-Cortes, Luis F, Benmarzouk-Hidalgo, Omar J, Fernández-Magdaleno, Tamara, BenMarzouk-Hidalgo, O. J., Llaves, Silvia, Espinosa, Nuria, Viciana, Pompeyo, López-Cortés, Luis F., Gutierrez-Valencia, Alicia, Gutiérrez Valencia, Alicia   +9 more
core   +1 more source

Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications [PDF]

, 2016
Nearly all HIV PIs and the integrase inhibitor elvitegravir require a pharmacokinetic enhancer in order to achieve therapeutic plasma concentrations at the desired dose and frequency. Whereas ritonavir has been the only available pharmacokinetic enhancer
Back, David, Marzolini, C, Gibbons, Sara, Khoo, S, Marzolini, Catia, Back, D, Khoo, Saye, Gibbons, S   +7 more
core   +1 more source

Pharmacist's role in managing drug–drug interactions in people with HIV receiving antiretroviral therapy or HIV pre‐exposure prophylaxis: A focus on polypharmacy and transitions of care in the United States

British Journal of Clinical Pharmacology, EarlyView.
Shawnalyn W. Sunagawa, Elizabeth M. Sherman, Melissa Badowski, David B. Cluck, Spencer H. Durham, Joshua P. Havens, Emily Huesgen, Justin K. Ma, Roxane Rohani, Eric G. Sahloff, Kristy M. Shaeer, Radhika S. Polisetty   +11 more
wiley   +1 more source

SARS‐CoV‐2 mRNA Vaccination Induces Neutralizing Antibodies and Type I IFN Changes in People Living With HIV

Journal of Medical Virology, Volume 98, Issue 8, August 2026.
ABSTRACT This study examined changes in anti‐Spike (anti‐S) antibodies (Abs) and type I interferon (IFN‐I) following the BNT162b2 vaccine in people living with HIV (PLWH) and analyzed the impact of demographic and immunological factors. In total, 75 PLWH and 28 healthy donors were followed at baseline (T0), at the second dose (T1), after the second ...
Federica Frasca, Luca Maddaloni, Alessandra D'Auria, Matteo Fracella, Ginevra Bugani, Carmen Falvino, Valentina Baccolini, Giuseppe Migliara, Francesca Aloisi, Letizia Santinelli, Enrico Palermo, Luca Bortolani, Alessandro Lazzaro, Giancarlo Ceccarelli, Ombretta Turriziani, Claudio Maria Mastroianni, Guido Antonelli, Gabriella d'Ettorre, Carolina Scagnolari   +18 more
wiley   +1 more source

Safety and Effectiveness of Glecaprevir/Pibrentasvir in Children and Adolescents With Chronic Hepatitis C: Reports From All‐Case Post‐Marketing Surveillance in Japan

Hepatology Research, Volume 56, Issue 8, Page 1202-1212, August 2026.
ABSTRACT Aim The aim of this all‐case post‐marketing study was to evaluate the real‐world safety and effectiveness in all children and adolescents with chronic hepatitis C with or without compensated cirrhosis treated with glecaprevir/pibrentasvir (G/P) in Japan. Methods This prospective, observational post‐marketing surveillance study was conducted at
Tatsuki Mizuochi, Katsuyoshi Kawana, Mariko Kobayashi, Eri Iwashita, Itaru Iwama, Daiki Abukawa, Hitoshi Tajiri   +6 more
wiley   +1 more source

Daclatasvir 30 mg/day is the correct dose for patients taking atazanavir/cobicistat [PDF]

, 2017
Contains fulltext : 169944.pdf (Publisher’s version ) (Open Access)BACKGROUND: Atazanavir is boosted with the cytochrome P450 (CYP) 3A4 inhibitor ritonavir.
Burger, D.M., Kanter, C.T.M.M. de, Smolders, E.J., Colbers, E.P.H., Velthoven-Graafland, K., Drenth, J.P.H., Smolders, E J, Colbers, E P H, de Kanter, C T M M, Burger, D M, Velthoven-Graafland, K, Drenth, J P H   +11 more
core   +1 more source